Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effects on Coronary Function in T2DM (DAPAMICRO)
NCT05392959Phase 4Terminated
- Sponsor
- Saint-Pierre University Hospital
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Fractional Flow Reserve at 6 months, Coronary Flow Reserve at 6 months and 1 more. Started Jun 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05392959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392959.